123I-meta-iodobenzylguanidine (MIBG) cardiac scintigraphy in α-synucleinopathies

Satoshi Orimo, Makiko Yogo, Tomohiko Nakamura, Masahiko Suzuki, Hirohisa Watanabe

研究成果: Review article査読

38 被引用数 (Scopus)

抄録

Cardiac meta-iodobenzylguanidine (MIBG) uptake on 123I-MIBG cardiac scintigraphy is reduced in patients with Lewy body disease such as Parkinson's disease (PD), dementia with Lewy bodies (DLB), and pure autonomic failure, and has been reported to be useful for differentiating PD from other parkinsonian syndromes, as well as DLB from Alzheimer disease (AD). Postmortem studies have shown that the number of tyrosine hydroxylase (TH)-immunoreactive nerve fibers of the heart was decreased in pathologically-confirmed Lewy body disease, supporting the findings of reduced cardiac MIBG uptake in Lewy body diseases. Now, reduced cardiac MIBG uptake can be a potential biomarker for the presence of Lewy bodies in the nervous system. 123I-MIBG cardiac scintigraphy can allow us to determine the presence of Lewy bodies.

本文言語English
ページ(範囲)122-133
ページ数12
ジャーナルAgeing Research Reviews
30
DOI
出版ステータスPublished - 01-09-2016
外部発表はい

All Science Journal Classification (ASJC) codes

  • バイオテクノロジー
  • 生化学
  • 加齢科学
  • 分子生物学
  • 神経学

フィンガープリント

「<sup>123</sup>I-meta-iodobenzylguanidine (MIBG) cardiac scintigraphy in α-synucleinopathies」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル